Research Review: Omega-3 supplementation to reduce antisocial behavior - a systematic review and meta-analysis of randomized controlled trials.

J Child Psychol PsychiatryApr 14, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Adrian Raine, Helena Q Saven

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed whether omega-3 supplementation reduces antisocial behavior. It included 25 randomized controlled trials involving 2,889 participants and analysed effects using independent studies and independent laboratories as units. Both analyses found small effects favouring supplementation: g = .13 and g = .14, respectively (p < .001). Evidence of publication bias was equivocal. Analyses by age, gender, dose, sample size, and study quality did not identify significant differences, although effects were larger among unmedicated participants. Combining these results with a separate meta-analysis yielded an effect size of g = .22 for externalizing behavior across 36 nonoverlapping trials.

Key findings

  • Across 25 RCTs and 2,889 participants, effects favoured omega-3 supplementation (g = .13 and .14; p < .001).
  • Stratified analyses by age, gender, dose, sample size, and study quality were nonsignificant; effects were larger in unmedicated participants.
  • Combined with a recent aggression meta-analysis, 36 nonoverlapping RCTs showed an overall externalizing-behavior effect size of g = .22.
  • Evidence of publication bias was equivocal, and the review rated study quality as good.

Why it matters

The pooled randomized-trial evidence suggests a statistically significant but small reduction in antisocial behavior with omega-3 supplementation. This provides a quantitative basis for considering omega-3 as a possible adjunct, while the modest effect and equivocal publication-bias evidence warrant measured interpretation. The findings do not establish which participant groups are most likely to benefit.

What to keep in mind

Evidence of publication bias was equivocal. Stratified analyses did not identify significant differences across the examined participant and study characteristics.

Source

Published in J Child Psychol Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.